Refractory celiac disease is a rare and specific complication of celiac disease and likely appears after many years of continued exposure to gluten. There are two types of refractory celiac disease and one in 200 patients with celiac disease will be diagnosed with refractory celiac disease type II (RCD-II). This condition increases the risk of mortality and developing lymphoma. Currently, there are very few treatment options available for those with RCD-II.

A research study is testing an investigational medication called AMG 714 for people with RCD-II. While the study is being conducted in San Diego, CA and New York City, the research team welcomes participants from across the country. The study sponsor will cover travel costs for qualified participants.

You may qualify to participate in this study if you are:

• At least 18 years old
• Diagnosed with celiac disease
• Still experiencing persistent or recurrent intestinal damage
• Having stomach symptoms
• Following a strict gluten-free diet for at least 6 months

If you qualify, you’ll receive at no cost:

• Study medication (active drug or placebo) for RCD-II
• Study related care and monitoring

If you volunteer and meet this and other study requirements, your participation may last up to 20 weeks. During that time, you’ll make up to 10 visits to the study offices, who will work with you to find convenient times for those visits. Health insurance and referrals are not required to participate.

The research study is being conducted at:

• Celiac Disease Center at Columbia University Medical Center
  New York, NY
• University of California – San Diego School of Medicine
  San Diego, CA

The research study is enrolling now. To see if you qualify or to ask questions about the study, please contact study representatives at [email protected].